No connection

Search Results

ALGS vs IMMP

ALGS
Aligos Therapeutics, Inc.
BEARISH
Price
$7.57
Market Cap
$46.6M
Sector
Healthcare
AI Confidence
85%
IMMP
Immutep Limited
BEARISH
Price
$0.31
Market Cap
$46.1M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
ALGS
--
IMMP
--
Forward P/E
ALGS
-1.42
IMMP
-1.42
P/B Ratio
ALGS
0.87
IMMP
6.75
P/S Ratio
ALGS
21.31
IMMP
5.82
EV/EBITDA
ALGS
0.3
IMMP
-4.41

Profitability

Gross Margin
ALGS
0.0%
IMMP
0.0%
Operating Margin
ALGS
-12907.7%
IMMP
-763.71%
Profit Margin
ALGS
0.0%
IMMP
0.0%
ROE
ALGS
-196.91%
IMMP
-61.85%
ROA
ALGS
-69.33%
IMMP
-32.1%

Growth

Revenue Growth
ALGS
-73.1%
IMMP
91.5%
Earnings Growth
ALGS
--
IMMP
--

Financial Health

Debt/Equity
ALGS
0.1
IMMP
0.01
Current Ratio
ALGS
3.9
IMMP
2.97
Quick Ratio
ALGS
3.67
IMMP
2.91

Dividends

Dividend Yield
ALGS
--
IMMP
--
Payout Ratio
ALGS
0.0%
IMMP
0.0%

AI Verdict

ALGS BEARISH

ALGS exhibits severe financial distress, reflected in a Piotroski F-Score of 0/9 and a lack of Altman Z-Score, indicating extreme bankruptcy risk. The company reports massive negative profitability metrics, including a -12,907.69% operating margin and -196.91% ROE, alongside a 73.1% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a high target price of $80.25, the stock trades at a premium valuation (Price/Sales of 21.31) with no earnings or cash flow generation. Insider sentiment is neutral, and technical trends are bearish, underscoring a lack of market confidence. The combination of deteriorating fundamentals and speculative valuation creates a high-risk profile.

Strengths
Analyst consensus is strongly bullish with a $80.25 target price
Recent quarterly EPS growth shows strong momentum (+85.4% YoY, +37.2% Q/Q)
Positive earnings surprises in 2 of the last 4 quarters (average +3.87%)
Risks
Piotroski F-Score of 0/9 signals extreme financial distress and operational failure
Negative operating margin (-12,907.69%) and ROE (-196.91%) reflect deep unprofitability
73.1% YoY revenue decline indicates business contraction
IMMP BEARISH

Immutep Limited presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only marginal financial stability. While the company shows strong YoY revenue growth of 91.50% and maintains a healthy current ratio of 2.97, these are overshadowed by a catastrophic operating margin of -763.71% and a total collapse in share price. The stock has lost approximately 78% of its value over the last year and 88.8% in the last month, signaling a severe lack of market confidence and a bearish technical trend of 0/100.

Strengths
Strong YoY revenue growth of 91.50%
Very low leverage with a Debt/Equity ratio of 0.01
Strong short-term liquidity (Current Ratio: 2.97)
Risks
Extreme cash burn evidenced by -763.71% operating margin
Severe price devaluation (down from 52-week high of $3.53 to $0.31)
Negative ROE (-61.85%) and ROA (-32.10%)

Compare Another Pair

ALGS vs IMMP: Head-to-Head Comparison

This page compares Aligos Therapeutics, Inc. (ALGS) and Immutep Limited (IMMP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile